作者
Giulio Cavalli, Alessandro Larcher, Alessandro Tomelleri, Corrado Campochiaro, Emanuel Della-Torre, Giacomo De Luca, Nicola Farina, Nicola Boffini, Annalisa Ruggeri, Andrea Poli, Paolo Scarpellini, Patrizia Rovere-Querini, Moreno Tresoldi, Andrea Salonia, Francesco Montorsi, Giovanni Landoni, Antonella Castagna, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna
发表日期
2021/4/1
期刊
The Lancet Rheumatology
卷号
3
期号
4
页码范围
e253-e261
出版商
Elsevier
简介
Background
Patients with severe COVID-19 develop a life-threatening hyperinflammatory response to the virus. Interleukin (IL)-1 or IL-6 inhibitors have been used to treat this patient population, but the comparative effectiveness of these different strategies remains undetermined. We aimed to compare IL-1 and IL-6 inhibition in patients admitted to hospital with COVID-19, respiratory insufficiency, and hyperinflammation.
Methods
This cohort study included patients admitted to San Raffaele Hospital (Milan, Italy) with COVID-19, respiratory insufficiency, defined as a ratio of the partial pressure of oxygen to the fraction of inspired oxygen of 300 mm Hg or less, and hyperinflammation, defined as serum C-reactive protein concentration of 100 mg/L or more or ferritin concentration of 900 ng/mL or more. The primary endpoint was survival, and the secondary endpoint was a composite of death or mechanical ventilation …
学术搜索中的文章
G Cavalli, A Larcher, A Tomelleri, C Campochiaro… - The Lancet Rheumatology, 2021